A new development in lung cancer research may be able to slow the progression of the disease, according to the Times News Network.
Lung cancer is one of the most common malignancies in the world, and researchers have discovered that a new vaccine, TG4010, decreases the speed of progression of advanced non-small-cell lung cancer (NSCLC) when used in conjunction with chemotherapy. The vaccine is said to “enhance” the effects of the chemotherapy drugs.
Approximately 80 percent of lung cancer patients are reportedly afflicted with NSCLC, many receiving diagnosis in its advanced stages. When it is detected that late, chemotherapy may be the only option. TG4010 could be a groundbreaking new treatment option if approved by the Food and Drug Administration, although further studies must be performed to present a proper case.
More than 40 percent of patients who enrolled in the study were progression free after six months of treatment with the vaccine, with participants reporting various side effects as anemia, low white blood cell count, low blood platelet count, fever, abdominal pain, and aching in the site of injection.
Scientists have opened another study to confirm the results found in this one, which was recently published in the medical journal Lancet Oncology.
Tags: cancer, chemotherapy, lung cancer, lung cancer treatment, lung cancer vaccine